MTNB stock gains on mid-stage data for meningitis therapy (NYSE:MTNB)
seekingalpha.com
news
2022-10-21 12:20:56

Hailshadow/iStock via Getty Images Clinical stage biotech Matinas BioPharma Holdings (NYSE:MTNB) announced Friday that its experimental therapy MAT2203 met the primary endpoint for a group of patients in a Phase 2 trial for cryptococcal meningitis. MAT2203 is an oral formulation of amphotericin B based on MTNB's lipid nanocrystal (LNC) platform technology. The EnACT study, supported by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) included a total of four cohorts.
